Recent Publications Highlighting Topics to be Discussed at PharmaLab 2025
Recommendation

3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
At PharmaLab 2025, taking place from 24 to 26 November in Neuss, a total of nine parallel conferences and two pre-conference workshops will be offered, featuring more than 100 presentations.
In the run-up to the event, several articles have been published that provide insights into current developments and discussions in the field of analytical quality control.
We would like to draw your attention to the following publications (access via publisher website; login or registration may be required):
From Method Validation to the Life-Cycle
European Biotechnology, Autumn Edition, Vol. 24, 2025, page 23
Author: Axel H. Schroeder
Link to website
AI in the pharmaceutical laboratory
Author: Dr Markus Funk
European Pharmaceutical Review, Issue 3, 2025, page 22
Link to website
These topics have also been published in German:
Von der Methodenvalidierung zum Life-Cycle - Analytik im Wandel
GIT Labor-Fachzeitschrift 6/2025, page 18
Author: Axel H. Schroeder
Read the article (PDF)
KI im Pharma-Labor
transkript 3/2025.
Author: Dr Markus Funk
Read the Article (Website)
Earlier articles, including coverage related to PharmaLab 2024, are available here.
We would also like to draw your attention to a recent interview:
#ChatsWithChaudhrey S6E45 w CONCEPT HEIDELBERG Axel Schroeder previewing #Pharmalab25 Nov 24-26
In this conversation, Rizwan Chaudhrey speaks with Axel Schröder about CONCEPT HEIDELBERG, its relationship with the ECA, the development of PharmaLab over the past 13 years, and what participants can expect from this year’s congress.
LinkedIn Post (overview and discussion)
YouTube Video (full interview)
Related GMP News
18.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
18.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1
18.12.2025PharmaLab 2025: Brief Summary of AQCG Track - Save the Date for 2026!
18.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
17.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
17.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity


